Quantcast
Last updated on April 16, 2014 at 7:15 EDT

Latest Neuland Laboratories Ltd. Stories

2014-04-08 08:30:25

--APIC Investment in Dedicated State-of-the-Art Facility Allows Neuland to Produce Competitively-Priced Pharmaceutical APIs and Intermediates for APIC-- HYDERABAD, India, April 8, 2014 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, announced that it has opened a new manufacturing...

2014-02-05 08:28:46

--Strengthening Margins and Continued Deleveraging Contribute to Improved Profitability as Year-Over-Year After-Tax Profits Rise-- HYDERABAD, India, Feb. 5, 2014 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the third quarter of fiscal year...

2013-11-08 08:27:28

--Company's Ongoing Drive to Strengthen Profitability Generates Increased Year-Over-Year After-Tax Profits-- HYDERABAD, India, Nov. 8, 2013 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the second quarter of fiscal year (FY) 2014, ended September...

2013-10-16 08:27:10

-- Neuland Ranked as a Top Regulatory Performer in Survey of Customers and Industry Leaders-- HYDERABAD, India, Oct. 16, 2013 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, today announced it has been awarded a 2013 CMO Leadership Award from Life Science Leader magazine in the...

2013-08-02 08:24:27

--Company Continues to Strengthen Profitability as After-Tax Profits Increase 157% Year-Over-Year-- HYDERABAD, India, Aug. 2, 2013 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the first quarter of fiscal year (FY) 2014, ended June 30, 2013....

2013-05-10 08:24:38

--Revenues Rose While Net Profits Increased Six-Fold Year-Over-Year-- HYDERABAD, India, May 10, 2013 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE: NEULANDLAB; BOM: 524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the 2013 fiscal year (FY) ended March 31, 2013. "Our initiatives to reduce costs and increase...

2013-03-12 08:29:40

--APIC Investment in Neuland's Facilities Will Allow Neuland to Produce Competitively-Priced Pharmaceutical Products for APIC-- HYDERABAD, India, March 12, 2013 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, today announced a manufacturing collaboration with Tokyo-based API...

2013-02-13 08:28:40

HYDERABAD, India, Feb. 13, 2013 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the third quarter of fiscal year (FY) 2013, ended December 31, 2012. Revenues for the third quarter of FY 2013 were $19.56 million (1.074 billion INR*), compared to revenues...

2012-11-09 08:27:45

HYDERABAD, India, Nov. 9, 2012 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE: NEULANDLAB; BOM: 524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced financial results for the second quarter of fiscal year (FY) 2013, ended September 30, 2012. Revenues for the second quarter of FY 2013 were $21.37 million (1.18 billion INR*),...

2012-08-10 06:22:02

HYDERABAD, India, Aug. 10, 2012 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE: NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and contract research and manufacturing services to customers located in 85 countries, today announced financial results for the first quarter of fiscal year (FY) 2013, ended June 30, 2012. "We are pleased that in the first quarter of the new fiscal year we reported the highest...